Corvus Pharmaceuticals, Inc. (CRVS) vs Seaport Therapeutics, Inc. Common Stock (SPTX)
A side-by-side comparison of Corvus Pharmaceuticals, Inc. and Seaport Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CRVS
Corvus Pharmaceuticals, Inc.
$10.56HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SPTX
Seaport Therapeutics, Inc. Common Stock
$17.37HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CRVS vs SPTX
growth of $100 · dividends reinvested · last 1yCRVS -30.5% (-30.5%/yr)SPTX -6.8% (-6.8%/yr)SPTX compounded faster over this window
CRVS SPTX
CRVS vs SPTX: by the numbers
- •SPTX is the larger company ($930M vs $888M market cap).
Metrics side by side
Valuation
| Metric | CRVS | SPTX |
|---|---|---|
| P/B ratio | 3.94 | 2.20 |
Profitability
| Metric | CRVS | SPTX |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -24.02% | N/A |
| ROIC | -25.25% | -36.95% |
Growth (annualized)
| Metric | CRVS | SPTX |
|---|---|---|
| Total return CAGR (5Y) | 17.88% | N/A |
Go deeper
Dig into the metrics
Corvus Pharmaceuticals ROESeaport Therapeutics, Inc. Common Stock ROECorvus Pharmaceuticals operating marginSeaport Therapeutics, Inc. Common Stock operating marginCorvus Pharmaceuticals revenue growthSeaport Therapeutics, Inc. Common Stock revenue growthCorvus Pharmaceuticals free cash flowSeaport Therapeutics, Inc. Common Stock free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.